

July 17, 2019

**BSE Limited**

Phiroze Jeejeebhoy Towers  
Dalal Street, Mumbai 400 001  
Scrip code: 532531

**The National Stock Exchange of India Limited**

Exchange Plaza, Bandra-Kurla Complex  
Bandra (E), Mumbai – 400 051  
Scrip code: STAR

Dear Sirs,

**Sub: Clarification on the Article appeared in Economic Times on July 17, 2019 titled  
“Strides plunges 8% as US FDA finds significant violation at facility”**

With reference to the above Article and your email query of today seeking news clarification,  
we wish to clarify as under:

- 1) The Company received the warning letter from US FDA relating to Strides Puducherry facility on July 2, 2019.
- 2) As required under Regulation 30 of SEBI LODR, the Company had intimated the Stock Exchanges about receipt of such warning letter on July 2, 2019, which also included the impact on Company's operations. Copy of the said intimation is attached as Annexure 1 for reference.

Trust the above clarifies.

**For Strides Pharma Science Limited,**



**Manjula Ramamurthy**  
**Company Secretary**



Encl: a/a

**Strides Pharma Science Limited**

(Formerly Strides Shasun Limited)

CIN: L24230MH1990PLC057062

Corp Off: Strides House, Bilekahalli, Bannerghatta Road, Bangalore - 560 076, India

Tel: +91 80 6784 0000 Fax: +91 80 6784 0700

Regd Off: 201, Devavrata, Sector 17, Vashi, Navi Mumbai – 400 703, India

Tel: +91 22 2789 2924 / 3199 Fax: +91 22 2789 2942

info@strides.com; www.strides.com

July 2, 2019

**BSE Limited**

Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400 001  
Scrip code: 532531

**The National Stock Exchange of India Limited**

Exchange Plaza, Bandra-Kurla Complex  
Bandra (E) Mumbai - 400 051  
Scrip code: STAR

Dear Sirs,

**Sub: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Further to our earlier communication dated May 6, 2019, relating to “USFDA classifies Strides Puducherry facility as Official Action Indicated (OAI)”, we wish to inform you that the Company has now received a warning letter from USFDA relating to Puducherry facility.

Puducherry site currently produces 6 ANDAs which will not get impacted by the current development. However, the 10 ANDAs pending approval from the site will get deferred till the site is reclassified.

Strides is committed to the highest standards of quality and compliance and will work collaboratively with the FDA to resolve all issues addressed in the warning letter

The Company retains its growth guidance for the US market.

You are requested to take the same on record.

**For Strides Pharma Science Limited,**



**Manjula Ramamurthy**  
Company Secretary

**Strides Pharma Science Limited**

(Formerly Strides Shasun Limited)

CIN: L24230MH1990PLC057062

Corp Off: Strides House, Bilekahalli, Bannerghatta Road, Bangalore - 560 076, India

Tel: +91 80 6784 0000 Fax: +91 80 6784 0700

Regd Off: 201, Devavrata, Sector 17, Vashi, Navi Mumbai – 400 703, India

Tel: +91 22 2789 2924 / 3199 Fax: +91 22 2789 2942

info@strides.com; www.strides.com